Brief: 60 Degrees Pharmaceuticals Registers Aclr8-Lr, A Phase Iib Study Of Tafenoquine For Treatment Of Covid-19, On Clinicaltrials.Gov
15/08/2023 12:35
60 Degrees Pharmaceuticals Inc SXTP.O :
* 60 DEGREES PHARMACEUTICALS REGISTERS ACLR8-LR, A PHASE IIB
STUDY
OF TAFENOQUINE FOR TREATMENT OF COVID-19, ON CLINICALTRIALS.GOV
* 60 DEGREES PHARMACEUTICALS INC - PLANS TO ENROLL PATIENTS
IN
ACLR8-LR, RECRUITED IN UP TO 30 OUT-PATIENT CLINICS ACROSS U.S.,
BEGINNING IN Q4 OF 2023
* 60 DEGREES PHARMACEUTICALS INC - ALSO PLANNING A SECOND,
LARGER
COVID-19 STUDY THAT IS ANTICIPATED TO COMMENCE IN 2024
Source text for Eikon: ID:nGNX4bvVcx
Further company coverage: SXTP.O
Recent news on 60 Degrees Pharmaceuticals
See all newsBrief: 60 Degrees Pharmaceuticals Says May Submit NDA For Tafenoquine To FDA Before End Of Q1 2028 - SEC Filing
U.S. RESEARCH ROUNDUP-Analog Devices, Intuit, NVIDIA
Brief: 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (Ndin) With FDA For Australian Chestnut Extract
NASDAQ RESUMED AT 10:06 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:55 AM